4-1BBxTAA bispecific antibody / Zymeworks - LARVOL DELTA

Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT, and Zanidatamab Mechanisms of Action at AACR Annual Meeting (Businesswire) - “Zymeworks…announced five presentations at the American Association for Cancer Research (AACR) Annual Meeting. The presentations highlight preclinical data that reveal new insights into the unique mechanisms of action of lead clinical candidate, zanidatamab, introduce Zymeworks’ fourth therapeutic platform, ProTECT™, and describe two new preclinical assets focused on the cytokine, IL-12, and the immune-oncology target, 4-1BB…Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action…ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics…IL-12 and 4-1BB Presentations; Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation.”

Preclinical • Biliary Cancer • Biliary Tract Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor